IL2 and breast cancer: In an earlier study, we showed that in women with metastatic breast cancer low dose IL-2, low dose GM-CSF, and eight Her2Bi armed ATC infusions induced cytotoxic T cell activity directed at SK-BR-3 breast cancer cell targets that could be detected up to 4 months or more after immunotherapy [30].